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Abstract
Background: To examine the prevalence of significant
interference from heterophile antibodies (HAb) in the
measurement of serum thyroglobulin (Tg), we evalu-
ated a large cohort of samples from patients with dif-
ferentiated thyroid carcinoma (DTC).
Methods: Serum Tg measurements were performed
in 406 serum samples before and after incubation of
each serum sample in heterophile-blocking tubes
(HBT) at room temperature for 1 h. We calculated the
difference between the original Tg value and the val-
ue obtained after HBT treatment. We considered any
sample showing an absolute percent difference )3
SD from the mean percent difference as being affect-
ed by HAb interference.
Results: We identified five patients (1%) as showing
interference from HAb. Of these, three (60%) showed
a false positive or falsely increased Tg concentration
without any recurrence following clinical work-up;
two (40%) showed a false negative or falsely reduced
Tg levels, and metastases were detected in both cases
by imaging procedures.
Conclusions: HAb may increase as well as reduce the
measured Tg in a significant number of patients. A
positive HAb interference should be suspected if Tg
elevation does not fit the clinical pictures. A negative
interference is a more challenging problem because
increases in Tg generally occur as the first sign of
recurrence of DTC. Therefore, treatment using HBT
tubes of all sera referred for Tg measurement should
be considered in order to prevent both unwarranted
investigations or therapy, and delayed diagnosis of
recurrence in patients affected by DTC.
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Introduction
Serum thyroglobulin (Tg) measurements are a major
tool for detecting recurrence of differentiated thyroid
carcinoma (DTC), provided that anti-Tg antibodies
(TgAb) are absent (1–3). Heterophile antibodies (HAb)
can bind to animal antigens or antibodies employed
in immunometric assays (4). HAbs can form a bridge
between the capture and detection antibody, leading
to a false positive result in absence of analyte, or to
a falsely higher result in presence of analyte (5).
Preissner and co-workers reported 32 false positive or
falsely increased serum Tg values from 1106 patients
with serum TgG1.00 ng/mL (2%) (6). However, HAb
may also bind to the capture antibody preventing the
binding of analyte and/or detection antibody causing
false negative or falsely low results (5). Accordingly,
we observed a case of HAb-induced false negative Tg
measurement in a patient with lymph-node metasta-
ses from DTC (7). Therefore, we decided to examine
the prevalence of significant HAb interferences in our
current Tg assay systematically by evaluating a large
cohort of samples with all concentrations of Tg.
Materials and methods
We included all TgAb-negative samples that had been
referred for Tg measurements to our laboratory by the
Department of Nuclear Medicine or outside customers dur-
ing October 2006–October 2008. For all samples, we deter-
mined the clinical indication for testing by review of the
medical record. Following routine measurement of Tg, all
samples were re-tested immediately for possible HAb inter-
ference as described below.
Tg and TgAb assay
All Tg and TgAb concentrations were measured using the
Immulite 2000 immunoassay system with the manufactu-
rer’s (DPC, Los Angeles, CA, USA) reagent packs and pro-
cedures. The functional sensitivity (i.e., lower limit of
detection) for our Tg assay is 0.36 ng/mL, as described pre-
viously (8). Samples with positive TgAb (i.e., )40 UI/mL)
were excluded from the study.
Identification of HAb interferences
For all study samples, we repeated the initial Tg measure-
ments after incubating 500 mL of serum from each sample
in heterophile-blocking tubes (HBT, Scantibodies, Santee,
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Table 1 Effects of rhTSH-stimulation on Tg concentrations
measured before and following HBT treatment in patients
with interferences from heterophile antibodies (Tg express-
ed as ng/mL).
onT4-Tg rhTSH-Tg
pre-HBT post-HBT pre-HBT post-HBT
1 -0.36 4.10 -0.36 10.7
2 0.98 12.4 1.2 26.2
3 4.1 -0.36 – –
4 1.9 -0.36 – –
5 5.7 0.8 – –
HBT, heterophile-blocking tubes; Tg, thyroglobulin.
CA, USA) at room temperature for 1 h. We calculated the
differences between the original Tg value and the measure-
ment obtained following HBT treatment, expressed as a per-
centage of the original result. We considered any sample
showing an absolute difference percentage of )3 SD from
the mean difference percentage as possibly being affected
by heterophile interference. The "3 SD cut-off was chosen
because, statistically, only 0.2% of measurements would be
expected to fall outside these limits, making this cut-off not
likely to be affected by random experimental error (i.e., sam-
ple manipulation).
Results
A total of 406 samples fulfilled the inclusion criteria,
representing 88% of all Tg measurements performed
during the study period. The remaining samples
(12%) were TgAb positive. Of the 406 samples, 404
were performed for follow-up of thyroid cancer and
two were performed in patients with neck lymph node
metastasis with unknown primary carcinoma. For 67
patients, serum Tg was measured during both thyrox-
ine treatment and following thyrotropin (TSH) stimu-
lation wthyroxine (T4) withdrawal: 42; rhTSH: 25x (134
samples). The Tg values of the original samples
ranged from -0.36 ng/mL to 2790 ng/mL, with a
mean of 3.7 ng/mL and a median of 1.2 ng/mL. These
were not significantly different from the correspond-
ing values following HBT treatment, which resulted
in a Tg measurement range of -0.36–2820 ng/mL,
with a mean of 4.1 ng/mL and a median of 1.1 ng/mL.
The mean difference between the original Tg values
and Tg values following HBT treatment was
0.47%"0.105% (SD) wmedian 0%x. Thus, the mean"3
SD limits were 0.16% and 0.78%, respectively. The
0.47% mean difference represents a decrease in
measured Tg following treatment with HBT. However,
approximately equal numbers of samples showed a
decrease or increase in Tg values following HBT treat-
ment. In two samples, the increase in Tg values fol-
lowing HBT treatment exceeded the 0.78% limit. The
pre-HBT treatment serum Tg values (during T4 in both
cases) in these samples were -0.36 and 0.98 ng/mL,
increasing to 4.10 ng/mL and 12.4 ng/mL, respective-
ly. Following rhTSH administration, no significant
changes occurred in pre-HBT treatment Tg measure-
ments in both patients. However, a significant
increase occurred after treatment with HBT (Table 1).
A small (8 mm) cervical lymph-node metastases was
detected in the first patient by neck ultrasound and
fine-needle cytology, which was subsequently con-
firmed by histology. Coexisting cervical and medias-
tinal metastases were found in the second patient,
and subsequently treated by surgery and radioiodine
administration. In three samples, the drop in Tg val-
ues following HBT treatment exceeded the 0.16% lim-
it. In two patients, serum Tg concentrations, during
treatment with T4, dropped from 4.1 and 1.9 ng/mL to
-0.36 ng/mL following HBT treatment, and from
5.7 ng/mL to 0.8 ng/mL in one other patient (Table 1).
No recurrences of DTC were detected by ultrasound
of the neck and 18Fluorodeoxyglucose-positron emis-
sion tomography/computed tomography (18FDG-PET/
CT). Further clinical follow-up at 14–26 months was
negative for these patients.
Discussion
The follow-up of patients with DTC is based primarily
on regular serum Tg measurements. The clinical con-
sequences of an artifactual elevation or decrease in
serum Tg concentrations can be considerable. In the
first scenario, additional investigations will ensue,
which may involve radiation exposure or even inva-
sive procedures. Additionally, the clinical trend to
occasionally treat thyroid cancer with radioiodine,
solely on the basis of increased Tg, can also result in
unnecessary therapy for patients without actual recur-
rence (9, 10). In the second scenario, a negative result
may falsely reassure both patient and physician and
effective treatments may be withheld. While TgAb
interference with Tg measurements are well known,
and still a challenge, few physicians are aware of the
potential problems due to HAb interference on Tg
measurements (11, 12). We remeasured serum Tg fol-
lowing treatment with HBT tubes for 406 samples,
and identified five samples (1%) showing HAb inter-
ference. Of these, three (60%) sera showed false positive
or falsely increased Tg, while two (40%) showed false
negative or falsely decreased Tg levels. Following
HBT treatment, a 0.47% mean decrease in measured
Tg was found. Possible bias introduced by sample
manipulation and HBT treatment itself could be
hypothesized. However, about equal numbers of sam-
ples showed a decrease and an increase in Tg values
following HBT treatment, as would be expected for
repeated measurements. Our data are in contrast with
those from Preissner and co-workers, that found 2%
false positive or falsely increased Tg results, but no
false negative or falsely decreased Tg which was
measured using an automated chemiluminometric Tg
assay. However, they excluded sera with Tg-1.00 ng/
mL. Consequently false negative or falsely decreased
results were unlikely to be detected in their series.
Our results show that HAb may increase as well as
reduce measured Tg in a significant number of
patients. Positive HAb interference should be sus-
pected if Tg elevation does not fit the clinical picture;
in this case, the simplest approach is to repeat the
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testing using a different assay. Samples that show
interference in one particular assay may not show any
problems using an assay from another manufacturer.
On the contrary, a negative HAb interference is a chal-
lenging problem because a Tg increase generally
occurs as the first sign of recurrence of DTC and false
negative results are generally difficult to detect on the
basis of clinical findings. In this instance, the role of
imaging procedures, primarily ultrasound of the neck,
still remains of pivotal importance in the clinical man-
agement of these patients. From the laboratory per-
spective, we propose that all sera referred for Tg
measurement be treated using HBT tubes. This
approach, in combination with appropriate imaging
procedures and good clinical judgement, can help
prevent unnecessary investigations or therapy and
delayed diagnosis of recurrences in patients with
DTC.
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